Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -17741.55% is 34% above its 1-year average of -26775.58%, near the high end of its 1-year range (-65785.53%–-16988.94%).
14.99% above its 12-month average of -20868.88%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -31282.67%.
EBITDA MARGIN
-17741.55%
EBITDA MARGIN AVG TTM
-20868.88%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.99%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ProKidney Corp.
Market Cap
$532.96M
EBITDA Margin
-17741.55%
TTM Avg
-20868.88%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$533.75M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$531.92M
EBITDA Margin
-91.00%
TTM Avg
-295.88%
3Y Avg
-8346.66%
5Y Avg
-8346.66%
Market Cap
$535.51M
EBITDA Margin
1.18%
TTM Avg
-15.78%
3Y Avg
-775.36%
5Y Avg
-845.24%
Market Cap
$537.01M
EBITDA Margin
-970.11%
TTM Avg
-861.99%
3Y Avg
-583.02%
5Y Avg
-735.09%
Market Cap
$538.17M
EBITDA Margin
-4782.00%
TTM Avg
-3061.67%
3Y Avg
-6701.43%
5Y Avg
-4552.91%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProKidney Corp. (PROK) | $532.96M | -17741.55% | -20868.88% | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $533.75M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $531.92M | -91.00% | -295.88% | -8346.66% | -8346.66% |
| Delcath Systems, Inc. (DCTH)vs › | $535.51M | 1.18% | -15.78% | -775.36% | -845.24% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $537.01M | -970.11% | -861.99% | -583.02% | -735.09% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $534.71M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $538.17M | -4782.00% | -3061.67% | -6701.43% | -4552.91% |
| Immix Biopharma, Inc. (IMMX)vs › | $520.90M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $522.29M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | -230187.80% | -372428.90% | -255754.79% | -154022.75% |
Gross Margin
100.0%
EBITDA Margin
-17741.5%
Operating Margin
-18477.8%
Net Margin
-10599.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -31282.67% |
| 2026-03-31 | -19246.90% |
| 2025-12-31 | -19520.89% |
| 2025-09-30 | -16988.94% |
| 2025-06-30 | -17304.98% |
| 2025-03-31 | -17299.13% |
| 2024-12-31 | -65785.53% |
